Adam Rock, MD
Medical Oncology · Duarte, CANPI 1477907715
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.7%), speaking fees and education — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Intuitive Surgical at 38.8% of the total. 2025 is the largest year on record at $1,797, 3.2 times the $562 reported in 2019. That places this record below the midpoint for medical oncology clinicians in CA, where the typical reported total is $4,042.
Across 72 payments — averaging $53.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$2K
- Novocure Inc.$231
- Galvanize Therapeutics, Inc$198
- E.r. Squibb & Sons, L.L.C.$156
- Lilly USA, LLC$142
- AstraZeneca$133
- plus $2K from 19 others
Across 126 payments — averaging $21,528 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$1M
- Taiho Oncology, Inc.$761K
- Boehringer Ingelheim Pharma GmbH & Co.kg$474K
- Merck$315K
- AbbVie$93K
- Coherus Oncology, Inc.$51K
- plus $2K from 1 others
What the payments were for
- Speaking & faculty fees$1,50039%
- Food & beverage$2,19457%
- Education$1775%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 1 | $1,500 |
| Novocure Inc. | 2 | $231 |
| Galvanize Therapeutics, Inc | 1 | $198 |
| E.r. Squibb & Sons, L.L.C. | 10 | $156 |
| Lilly USA, LLC | 4 | $142 |
| AstraZeneca(2 entities) | 4 | $133 |
| Seagen Inc. | 1 | $126 |
| Bristol Myers Squibb | 5 | $122 |
| Johnson & Johnson | 1 | $117 |
| Sanofi | 5 | $113 |
| Aadi Bioscience, Inc. | 1 | $105 |
| Pfizer | 6 | $104 |
| Sanofi-aventis U.S. LLC | 2 | $99 |
| Merck | 4 | $98 |
| Amgen | 4 | $97 |
| Deciphera Pharmaceuticals Inc. | 3 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $88 |
| Exelixis Inc. | 3 | $73 |
| Mirati Therapeutics, Inc. | 2 | $67 |
| Incyte Corporation | 3 | $62 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $45 |
| Stemline Therapeutics Inc. | 2 | $38 |
| Daiichi Sankyo Inc. | 1 | $31 |
| Eisai Inc. | 1 | $21 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,500
- ALIYA SYSTEM$198
- PADCEV$126
- RYBREVANT$117
- FYARRO$105
- OPTUNE LUA (NOVOTTF-200T)$104
How this compares
$3,871 in reported general payments places this provider in the 45th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 143 | $2,439,768 |
| AlecensaAlectinib Hcl | 19 | $355,057 |
| LorbrenaLorlatinib | 16 | $272,512 |
| XtandiEnzalutamide | 18 | $240,517 |
| InlytaAxitinib | 12 | $167,649 |
| Pazopanib Hcl | 12 | $93,724 |
| OrgovyxRelugolix | 21 | $56,451 |
| Abiraterone Acetate | 15 | $39,804 |
| Dexamethasone | 43 | $751 |
| Prochlorperazine Maleate | 49 | $609 |
| Ondansetron Hcl | 51 | $409 |
| Gabapentin | 20 | $269 |
| Ondansetron OdtOndansetron | 17 | $187 |
| Amlodipine Besylate | 15 | $160 |
| Prednisone | 11 | $77 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $133 | $2,439,768143 claims |
| PfizerLorbrena, Inlyta | $104 | $440,16128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 379 medical oncology providers in California.
Other medical oncology in Duarte
- Daneng LiDuarte$467K
- Howard WestDuarte$426K
- Christine LovlyDuarte$362K
- Marwan FakihDuarte$203K
- Erminia MassarelliDuarte$176K
- Ravi SalgiaDuarte$142K
- Tanya DorffDuarte$136K
- Karen ReckampDuarte$132K
- Cy SteinDuarte$122K
- Joseph ChaoDuarte$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.